Pediatric Withdrawal Identification and Management

Abstract

Sedation administered by continuous intravenous infusion is commonly used in the pediatric intensive care unit to facilitate and maintain safe care of children during critical illness. Prolonged use of sedatives, including opioids, benzodiazepines, and potentially other adjunctive agents, is known to cause withdrawal symptoms when they are stopped abruptly or weaned quickly. In this review, the common signs and symptoms of opioid, benzodiazepine, and dexmedetomidine withdrawal will be discussed. Current tools used to measure withdrawal objectively, as well as withdrawal prevention and management strategies, will be discussed.

Keywords

pediatric withdrawal - pediatric narcotic withdrawal - pediatric benzodiazepine withdrawal - dexmedetomidine withdrawal

• References

• 1 Birchley G. Opioid and benzodiazepine withdrawal syndromes in the paediatric intensive care unit: a review of recent literature. Nurs Crit Care 2009; 14 (1) 26-37
• 2 Jenkins IA, Playfor SD, Bevan C, Davies G, Wolf AR. Current United Kingdom sedation practice in pediatric intensive care. Paediatr Anaesth 2007; 17 (7) 675-683
• 3 Anand KJ, Willson DF, Berger J , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics 2010; 125 (5) e1208-e1225
• 4 Tobias JD. Dexmedetomidine: are there going to be issues with prolonged administration?. J Pediatr Pharmacol Ther 2010; 15 (1) 4-9
• 5 Miller JL, Allen C, Johnson PN. Neurologic withdrawal symptoms following abrupt discontinuation of a prolonged dexmedetomidine infusion in a child. J Pediatr Pharmacol Ther 2010; 15 (1) 38-42
• 6 Honey BL, Harrison DL, Gormley AK, Johnson PN. Evaluation of adverse events noted in children receiving continuous infusions of dexmedetomidine in the intensive care unit. J Pediatr Pharmacol Ther 2010; 15 (1) 30-37
• 7 American Academy of Pain Medicine, the American Pain Society and the American Society of Addition Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ 2001; 100 (5) 28-29
• 8 Ista E, van Dijk M, Gamel C, Tibboel D, de Hoog M. Withdrawal symptoms in children after long-term administration of sedatives and/or analgesics: a literature review. “Assessment remains troublesome”. Intensive Care Med 2007; 33 (8) 1396-1406
• 9 Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 2006; 147 (Suppl. 01) S153-S162
• 10 Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. Crit Care Med 2000; 28 (6) 2122-2132
• 11 Bateson AN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 2002; 8 (1) 5-21
• 12 Anand KJ, Ingraham J. Pediatric. Tolerance, dependence, and strategies for compassionate withdrawal of analgesics and anxiolytics in the pediatric ICU. Crit Care Nurse 1996; 16 (6) 87-93
• 13 Fernández-Carrión F, Gaboli M, González-Celador R , et al. Withdrawal syndrome in the pediatric intensive care unit. Incidence and risk factors. Med Intensiva 2013; 37 (2) 67-74 (in English, in Spanish)
• 14 Franck LS, Naughton I, Winter I. Opioid and benzodiazepine withdrawal symptoms in paediatric intensive care patients. Intensive Crit Care Nurs 2004; 20 (6) 344-351
• 15 Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med 2007; 8 (2) 115-131
• 16 Buck ML. Dexmedetomidine use in pediatric intensive care and procedural sedation. J Pediatr Pharmacol Ther 2010; 15 (1) 17-29
• 17 Burbano NH, Otero AV, Berry DE, Orr RA, Munoz RA. Discontinuation of prolonged infusions of dexmedetomidine in critically ill children with heart disease. Intensive Care Med 2012; 38 (2) 300-307
• 18 Finnegan LP, Kron RE, Connaughton JF, Emich JP. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm 1975; 12 (1-2) 19-32
• 19 Finnegan LP, Connaughton Jr JF, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2 (1-2) 141-158
• 20 Cunliffe M, McArthur L, Dooley F. Managing sedation withdrawal in children who undergo prolonged PICU admission after discharge to the ward. Paediatr Anaesth 2004; 14 (4) 293-298
• 21 Hudak ML, Tan RC ; Committee on drugs; Committee on fetus and newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012; 129 (2) e540-e560
• 22 Franck LS, Harris SK, Soetenga DJ, Amling JK, Curley MA. The Withdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatr Crit Care Med 2008; 9 (6) 573-580
• 23 Franck LS, Scoppettuolo LA, Wypij D, Curley MA. Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. Pain 2012; 153 (1) 142-148
• 24 Ista E, van Dijk M, de Hoog M, Tibboel D, Duivenvoorden HJ. Construction of the Sophia Observation withdrawal Symptoms-scale (SOS) for critically ill children. Intensive Care Med 2009; 35 (6) 1075-1081
• 25 Ista E, de Hoog M, Tibboel D, Duivenvoorden HJ, van Dijk M. Psychometric evaluation of the Sophia Observation withdrawal symptoms scale in critically ill children. Pediatr Crit Care Med 2013; 14 (8) 761-769
• 26 Oschman A, McCabe T, Kuhn RJ. Dexmedetomidine for opioid and benzodiazepine withdrawal in pediatric patients. Am J Health Syst Pharm 2011; 68 (13) 1233-1238
• 27 Johnson PN, Boyles KA, Miller JL. Selection of the initial methadone regimen for the management of iatrogenic opioid abstinence syndrome in critically ill children. Pharmacotherapy 2012; 32 (2) 148-157
• 28 Methadone In: Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. Hudson, Ohio: Lexi-Comp Inc; ; October 20, 2014